ANAHEIM -- When interventionalists at the Transcatheter Cardiovascular Therapeutics meeting heard the first report of the ORBITA trial last month showing stenting no better than a sham procedure for stable angina, it was clear there would be more to the story.
Here at the American Heart Association's Scientific Sessions, the trial was the talk of the hallways. In this exclusive video interview, 鶹ý pulled in perspectives from a wide range of leading cardiologists:
- Bernard Gersh, MB, ChB, DPhil, of the Mayo Clinic in Rochester, Minn.
- Roxana Mehran, MD, of Mount Sinai School of Medicine, in New York City
- C. Noel Bairey Merz, MD, of Cedars-Sinai Medical Center in Los Angeles
- Peter Block, MD, of Emory University in Atlanta
- Robert Yeh, MD, of Beth Israel Deaconess Medical Center in Boston
- Kim Eagle, MD, of the University of Michigan in Ann Arbor
- Richard Chazal, MD, immediate-past president of the American College of Cardiology
- David Brown, MD, of Washington University in St. Louis, Missouri
The trial was published in. 鶹ý has the full details of the findings here.
Watch all our exclusive video from study authors and leading cardiologists at AHA 2017